Thomas Fratacci - Biotech Acquisition CFO Treasurer

BIOTDelisted Stock  USD 10.15  0.00  0.00%   

Insider

Thomas Fratacci is CFO Treasurer of Biotech Acquisition Co
Age 45
Phone212 227 1905

Biotech Acquisition Management Efficiency

Biotech Acquisition's management efficiency ratios could be used to measure how well Biotech Acquisition manages its routine affairs as well as how well it operates its assets and liabilities.
Biotech Acquisition Co currently holds 153.35 K in liabilities with Debt to Equity (D/E) ratio of 3.48, implying the company greatly relies on financing operations through barrowing. Biotech Acquisition has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biotech Acquisition's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Niall HoganIntegral Ad Science
N/A
R EsperUnited Natural Foods
N/A
William LaFoyBoston Omaha Corp
63
Tania SecorIntegral Ad Science
N/A
Anil SukumaranIntegral Ad Science
N/A
Lisa UtzschneiderIntegral Ad Science
56
Shayn WallaceJohn B Sanfilippo
52
William KruegerThe Andersons
58
Hagit ShamirBOS Better Online
N/A
John KrausThe Andersons
N/A
Bradford BrinerBoston Omaha Corp
43
Oleg BershadskyIntegral Ad Science
42
Mark BushwayUnited Natural Foods
N/A
Noah WebsterIntegral Ad Science
51
Brendan KeatingBoston Omaha Corp
38
Vishnu SrinivasanBoston Omaha Corp
41
Steven McGhieBoston Omaha Corp
58
John ClareUnited Natural Foods
53
Helene MonatIntegral Ad Science
N/A
Lisa NadlerIntegral Ad Science
62
Robert JanecekIntegral Ad Science
N/A
Biotech Acquisition Company does not have significant operations. The company was incorporated in 2020 and is based in New York, New York. Biotech Acquisition is traded on NASDAQ Exchange in the United States. Biotech Acquisition Co (BIOT) is traded on NASDAQ Exchange in USA and employs 4 people.

Management Performance

Biotech Acquisition Leadership Team

Elected by the shareholders, the Biotech Acquisition's board of directors comprises two types of representatives: Biotech Acquisition inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotech. The board's role is to monitor Biotech Acquisition's management team and ensure that shareholders' interests are well served. Biotech Acquisition's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotech Acquisition's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Shleifer, Chairman CEO
Ivan Jarry, Chief Officer
Albert MBA, Chief Director
Thomas Fratacci, CFO Treasurer

Biotech Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biotech Acquisition a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Biotech Stock

If you are still planning to invest in Biotech Acquisition check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biotech Acquisition's history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Fundamental Analysis
View fundamental data based on most recent published financial statements
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators